Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker KYMR
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Brian Adams Chief Legal Officer | KYMR Kymera Therapeutics, Inc. | Sale | 2,137 | $117.57 | $251.2K Sale | Form 4 ↗ |
| Sep 4, 2026 | Brian Adams Chief Legal Officer | KYMR Kymera Therapeutics, Inc. | Sale | 3,025 | $116.81 | $353.4K Sale | Form 4 ↗ |
| Sep 4, 2026 | Brian Adams Chief Legal Officer | KYMR Kymera Therapeutics, Inc. | Sale | 1,209 | $115.55 | $139.7K Sale | Form 4 ↗ |
| Jul 7, 2026 | Nello Mainolfi Chief Executive Officer, Director | KYMR Kymera Therapeutics, Inc. | Sale | 50,000 | $119.00 | $6.0M Sale | Form 4 ↗ |
| Jul 1, 2026 | Noah Goodman Chief Business Officer | KYMR Kymera Therapeutics, Inc. | Sale | 3,389 | $114.29 | $387.3K Sale | Form 4 ↗ |
| Jul 1, 2026 | Nello Mainolfi Chief Executive Officer, Director | KYMR Kymera Therapeutics, Inc. | Sale | 3,336 | $116.56 | $388.8K Sale | Form 4 ↗ |
| Jul 1, 2026 | Nello Mainolfi Chief Executive Officer, Director | KYMR Kymera Therapeutics, Inc. | Sale | 44,050 | $115.69 | $5.1M Sale | Form 4 ↗ |
| Jul 1, 2026 | Nello Mainolfi Chief Executive Officer, Director | KYMR Kymera Therapeutics, Inc. | Sale | 24,105 | $114.96 | $2.8M Sale | Form 4 ↗ |
| Jul 1, 2026 | Nello Mainolfi Chief Executive Officer, Director | KYMR Kymera Therapeutics, Inc. | Sale | 6,626 | $113.98 | $755.2K Sale | Form 4 ↗ |
| Jul 1, 2026 | Nello Mainolfi Chief Executive Officer, Director | KYMR Kymera Therapeutics, Inc. | Sale | 1,883 | $112.80 | $212.4K Sale | Form 4 ↗ |
| Jun 30, 2026 | Bruce N. Jacobs Chief Financial Officer | KYMR Kymera Therapeutics, Inc. | Sale | 3,200 | $117.70 | $376.6K Sale | Form 4 ↗ |
| Jun 30, 2026 | Bruce N. Jacobs Chief Financial Officer | KYMR Kymera Therapeutics, Inc. | Sale | 6,153 | $116.99 | $719.8K Sale | Form 4 ↗ |
| Jun 30, 2026 | Bruce N. Jacobs Chief Financial Officer | KYMR Kymera Therapeutics, Inc. | Sale | 7,971 | $115.82 | $923.2K Sale | Form 4 ↗ |
| Jun 30, 2026 | Bruce N. Jacobs Chief Financial Officer | KYMR Kymera Therapeutics, Inc. | Sale | 51,375 | $114.77 | $5.9M Sale | Form 4 ↗ |
| Jun 30, 2026 | Bruce N. Jacobs Chief Financial Officer | KYMR Kymera Therapeutics, Inc. | Sale | 4,110 | $114.19 | $469.3K Sale | Form 4 ↗ |
| Jun 30, 2026 | Bruce N. Jacobs Chief Financial Officer | KYMR Kymera Therapeutics, Inc. | Sale | 1,100 | $112.79 | $124.1K Sale | Form 4 ↗ |
| Jun 30, 2026 | Bruce N. Jacobs Chief Financial Officer | KYMR Kymera Therapeutics, Inc. | Sale | 1,700 | $111.57 | $189.7K Sale | Form 4 ↗ |
| Jun 30, 2026 | Bruce N. Jacobs Chief Financial Officer | KYMR Kymera Therapeutics, Inc. | Sale | 1,500 | $110.54 | $165.8K Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 130 | $111.20 | $14.5K Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 1,078 | $110.67 | $119.3K Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 1,104 | $109.75 | $121.2K Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 1,498 | $108.28 | $162.2K Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 2,698 | $107.76 | $290.7K Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 2,133 | $106.63 | $227.4K Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 770 | $105.78 | $81.5K Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 934 | $111.20 | $103.9K Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 7,723 | $110.67 | $854.7K Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 7,968 | $109.75 | $874.5K Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 10,848 | $108.28 | $1.2M Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 19,419 | $107.76 | $2.1M Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 14,798 | $106.63 | $1.6M Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 5,549 | $105.78 | $587.0K Sale | Form 4/A ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 157 | $111.20 | $17.5K Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 1,199 | $110.67 | $132.7K Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 1,239 | $109.75 | $136.0K Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 1,688 | $108.28 | $182.8K Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 907 | $111.20 | $100.9K Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 7,602 | $110.67 | $841.3K Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 7,833 | $109.75 | $859.7K Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 10,658 | $108.28 | $1.2M Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 3,024 | $107.76 | $325.9K Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 2,318 | $106.63 | $247.2K Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 848 | $105.78 | $89.7K Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 19,093 | $107.76 | $2.1M Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 14,613 | $106.63 | $1.6M Sale | Form 4 ↗ |
| Jun 29, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 5,471 | $105.78 | $578.7K Sale | Form 4 ↗ |
| Jun 26, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 1,729 | $118.66 | $205.2K Sale | Form 4 ↗ |
| Jun 26, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 3,069 | $117.85 | $361.7K Sale | Form 4 ↗ |
| Jun 26, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 1,701 | $117.09 | $199.2K Sale | Form 4 ↗ |
| Jun 26, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | Sale | 952 | $115.69 | $110.1K Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:44 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances